AMLX vs AVBP: fair value comparison
Amylyx Pharmaceuticals, Inc. and ArriVent BioPharma, Inc. Common Stock · Updated 2026-10-19
AMLX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. AVBP has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, AMLX currently ranks higher by quality score.
| AMLX | AVBP | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $26.34 | $16.66 |
| 12-month range | $11.38–$39.66 | $15.09–$34.74 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #218 of 301 Healthcare | #220 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: AMLX fair value analysis · AVBP fair value analysis